568 related articles for article (PubMed ID: 17331821)
1. A cross-sectional study of bone turnover markers in healthy premenopausal women.
de Papp AE; Bone HG; Caulfield MP; Kagan R; Buinewicz A; Chen E; Rosenberg E; Reitz RE
Bone; 2007 May; 40(5):1222-30. PubMed ID: 17331821
[TBL] [Abstract][Full Text] [Related]
2. Determinants of bone turnover markers in healthy premenopausal women.
Adami S; Bianchi G; Brandi ML; Giannini S; Ortolani S; DiMunno O; Frediani B; Rossini M;
Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
[TBL] [Abstract][Full Text] [Related]
3. Establishing a reference range for bone turnover markers in young, healthy women.
Glover SJ; Garnero P; Naylor K; Rogers A; Eastell R
Bone; 2008 Apr; 42(4):623-30. PubMed ID: 18289953
[TBL] [Abstract][Full Text] [Related]
4. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.
Ardawi MS; Maimani AA; Bahksh TA; Rouzi AA; Qari MH; Raddadi RM
Bone; 2010 Oct; 47(4):804-14. PubMed ID: 20659600
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
6. Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study.
Martínez J; Olmos JM; Hernández JL; Pinedo G; Llorca J; Obregón E; Valero C; González-Macías J
Clin Chim Acta; 2009 Nov; 409(1-2):70-4. PubMed ID: 19737549
[TBL] [Abstract][Full Text] [Related]
7. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and history of oral contraceptive use.
Fortney JA; Feldblum PJ; Talmage RV; Zhang J; Godwin SE
J Reprod Med; 1994 Feb; 39(2):105-9. PubMed ID: 8169923
[TBL] [Abstract][Full Text] [Related]
9. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
10. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
11. Levels of biochemical bone marker procollagen type I N-propeptide (PINP) in Thai women aged 40-70 years.
Boonyanurak P; Wilawan K
J Med Assoc Thai; 2009 Jul; 92(7):873-7. PubMed ID: 19626803
[TBL] [Abstract][Full Text] [Related]
12. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
13. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
14. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women.
Gass ML; Kagan R; Kohles JD; Martens MG
Menopause; 2008; 15(4 Pt 1):667-75. PubMed ID: 18327152
[TBL] [Abstract][Full Text] [Related]
15. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
[TBL] [Abstract][Full Text] [Related]
16. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
[TBL] [Abstract][Full Text] [Related]
17. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
[TBL] [Abstract][Full Text] [Related]
19. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women.
Kruger MC; Booth CL; Coad J; Schollum LM; Kuhn-Sherlock B; Shearer MJ
Nutrition; 2006; 22(11-12):1120-8. PubMed ID: 17030114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
